Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients
|Conditions:||Peripheral Vascular Disease, Cardiology|
|Therapuetic Areas:||Cardiology / Vascular Diseases|
|Age Range:||18 - 80|
|Start Date:||January 2003|
|Contact:||Tanuj K Kamineni|
|Phone:||404 712 0168|
TITLE: Anti-Ischemic effects of Abciximab(Reopro)
PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small
stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable
statin dose or not on a statin. Statin= cholesterol lowering drug(ie, lipitor, zocor).
INTERVENTION: Heparin vs. heparin + abciximab during PCI
PURPOSE: Measure the effects of abciximab on special healing blood stem cells
(EPC's-Endothelial Progenitor Cells), on inflammation, on oxidative stress and on
microvascular blood flow.
1. 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28.
2. Measurement of blood flow in selected suitable patients
3. 10 minute questionnaire before discharge and on visit on day 28.
1. Have either:
- clinical history of anginal symptoms or positive stress test or
- in stent restenosis
2. Have an angiographic >70% coronary artery stenosis that will be treated with coronary
angioplasty or stenting procedure
3. For at least four weeks prior to the procedure have been on, no Hmgcoa- reductase
inhibitor or a stable statin dose
4. negative pregnancy test
5. are able to give informed consent
1. Coronary intervention within four weeks prior to enrollment.
2. Treatment with abciximab antagonistwithin four weeks.
3. treatment with thrombolytic therapy within 48 hours
4. MI within 2 months.
5. recent infections
6. general anesthesia within 3 months.
7. renal failure
We found this trial at